These findings challenge dogma regarding extremely elevated FMR1 increases in FXTAS and implicate glial dysregulation as a critical facet of premutation pathophysiology, representing potential unique therapeutic targets directly derived from the human condition. The gene discussed is FMR1; the disease is fragile X-associated tremor/ataxia syndrome.